<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154775</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-C2017003</org_study_id>
    <nct_id>NCT03154775</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of C-CAR011 in B-NHL Patients</brief_title>
  <official_title>Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy&#xD;
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy&#xD;
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The study&#xD;
      will include the following sequential phases: Screening, Pre-Treatment (Cell Product&#xD;
      Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety(Incidence of adverse events)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission(DOR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Refractory or Relapsed Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CAR011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-CAR011</intervention_name>
    <description>Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>
    <arm_group_label>C-CAR011</arm_group_label>
    <other_name>Anti-CD19 Chimeric Antigen Receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteered to participate in this study and signed informed consent&#xD;
&#xD;
          2. Age 18-70 years old, male or female&#xD;
&#xD;
          3. Relapsed or refractory B cell non-Hodgkin's lymphoma&#xD;
&#xD;
               -  1 Histologically diagnosed as DLBCL(including PMBCL) or follicular lymphoma(grade&#xD;
                  Ⅲb) according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines&#xD;
                  (1st edition 2017)&#xD;
&#xD;
                    1. Progressive disease after the last standard chemotherapy regimens&#xD;
&#xD;
                    2. Stable disease after the last standard chemotherapy regimens&#xD;
&#xD;
                    3. Relapsed within 12 months after prior autologous SCT&#xD;
&#xD;
               -  2 Follicular lymphoma(stage Ⅲ-Ⅳ)(grade Ⅰ-Ⅲa)&#xD;
&#xD;
                    1. At least 2 prior combination chemotherapy regimens (not including single&#xD;
                       agent monoclonal antibody (Rituxan) therapy&#xD;
&#xD;
                    2. Less than 1 year between last chemotherapy and progression&#xD;
&#xD;
               -  3 Mantle cell lymphoma&#xD;
&#xD;
                    1. Beyond 1st CR with relapsed or persistent disease and not eligible or&#xD;
                       appropriate for conventional allogeneic or autologous SCT&#xD;
&#xD;
                    2. Disease relapsed or progressed after most recent therapy&#xD;
&#xD;
                    3. Relapsed within 12 months after prior autologous SCT&#xD;
&#xD;
          4. All subjects must have received adequate prior therapy including anti-CD20 monoclonal&#xD;
             antibody (unless tumor is CD20-negative) and an anthracycline containing chemotherapy&#xD;
             regimen. The standardized treatment regimens reference to NCCN non-Hodgkin lymphoma&#xD;
             Clinical Practice Guidelines (2017 Version 1)&#xD;
&#xD;
          5. At least one measurable lesion per revised IWG Response Criteria (the longest diameter&#xD;
             of the tumor ≥ 1.5 cm)&#xD;
&#xD;
          6. Expected survival ≥ 12 weeks&#xD;
&#xD;
          7. ECOG score 0-1&#xD;
&#xD;
          8. Adequate pulmonary, hepatic, renal and cardiac function&#xD;
&#xD;
          9. At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy&#xD;
             therapy) prior to leukapheresis,or at least 4 weeks from monoclonal antibody therapy&#xD;
             prior to CAR T infusion&#xD;
&#xD;
         10. No contraindications of leukapheresis&#xD;
&#xD;
         11. Female subjects in childbearing age, their serum or urine pregnancy test must be&#xD;
             negative, and must agree to take effective contraceptive measures during the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with CAR T therapy or any other genetically modified T cell therapy&#xD;
&#xD;
          2. Relapse after allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          3. Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis&#xD;
             is allowed), Prophylactic antibiotic, antiviral and antifungal treatment is&#xD;
             permissible&#xD;
&#xD;
          4. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as&#xD;
             acquired, congenital immune deficiency diseases, including but not limited to&#xD;
             HIV-infected people&#xD;
&#xD;
          5. Patients with class III and IV heart failure according to the NYHA Heart Failure&#xD;
             Classifications&#xD;
&#xD;
          6. QT interval prolongation≥450 ms&#xD;
&#xD;
          7. A history of epilepsy or other central nervous system disorders&#xD;
&#xD;
          8. No evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging&#xD;
&#xD;
          9. The patient had a history of other primary cancers, with the following exceptions&#xD;
&#xD;
               -  1 Excisional non-melanoma such as cutaneous basal cell carcinoma&#xD;
&#xD;
               -  2 Cured in situ carcinoma such as cervical cancer, bladder cancer or breast&#xD;
                  cancer&#xD;
&#xD;
         10. Subjects with any autoimmune disease or any immune deficiency disease or other disease&#xD;
             in need of immunosuppressive therapy&#xD;
&#xD;
         11. Used of systemic steroids within two weeks (using inhaled steroids is an exception)&#xD;
&#xD;
         12. Women who are pregnant or lactating or have breeding intent in 6 months&#xD;
&#xD;
         13. Participated in any other clinical trial within three months&#xD;
&#xD;
         14. The investigators believe that any increase in the risk of the subject or interference&#xD;
             with the results of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <phone>0086-021-66111019</phone>
    <email>lab7182@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Li, MD,Ph.D.</last_name>
    <phone>0086-021-66111015</phone>
    <email>lilyforever76@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology,Shanghai Tongji Hospital, Tongji University School of Medicin</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aibin Liang, MD,Ph.D.</last_name>
      <phone>0086-021-66111019</phone>
      <email>lab7182@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ping Li, MD,Ph.D.</last_name>
      <phone>0086-021-66111015</phone>
      <email>lilyforever76@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 13, 2017</last_update_submitted>
  <last_update_submitted_qc>May 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

